Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Libtayo in advanced melanoma
NCT03002376Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2017
- Primary completion
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of cemiplimab in melanoma, sponsored by Regeneron Pharmaceuticals. Primary endpoint: Correlation between changes in the tumor microenvironment and the change in tumor volume following REGN2810 treatment versus baseline at 24 weeks. Started Apr 2017; status: completed.
02
Drugs
cemiplimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03002376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002376.